News

Cannabis: A secret weapon against superbugs

Arti Dumbrepatil
Nov. 5, 2020

Although the novel coronavirus has grabbed most headlines in recent months, antimicrobial resistance remains a critical challenges for public health agencies around the world, notably the rapid spread of methicillin-resistant Staphylococcus aureus, known as MRSA. In the fight against this superbug, Eric Brown employs an unconventional research approach, developing novel drug molecules from natural products, specifically from Cannabis sativa.

“Natural products have the potential to solve the issue of drug resistance in pathogenic bacteria,” Brown said. “This is a great resource that we haven’t fully investigated. Researchers in academia have the tools and ability to pursue outlandish ideas, which can be steered to the development of new therapeutic agents.”

As the Canada research chair in microbial chemical biology and a professor of biochemistry and biomedical sciences at McMaster University, Brown leads an interdisciplinary research team that has detected a cannabinoid called cannabigerol or CBG.

“Cannabis plants are known to produce compounds to block the invading pathogens,” Brown said. “We decided to take benefit of the regulatory environment in Canada and use Cannabis to tackle the emerging threat of drug resistance.”

Since the 2018 legalization of marijuana in Canada, Brown’s lab has been studying the antibiotic potential of cannabis. This research has some stigma associated with it, Brown said, but there is circumstantial evidence for medicinal use of the plant. The team established the antibacterial properties of CBG and found that it was highly effective at controlling MRSA in mice. Controlling MRSA is challenging as it is resistant to all known beta-lactam antibiotics. Further, the lab’s study published in the journal American Chemical Society Infectious Diseases found that CBG targeted the cell membrane of bacteria and prevented formation of biofilms, bacterial communities that adhere to each other and surfaces, and also destroyed existing biofilms.

Brown-lab-890x489.jpg
Courtesy of the Brown Lab
From left, postdoctoral fellow Omar El-Halfawy, Eric Brown, and research associate Maya Farha are authors of the lab’s study of CBG.

The team also demonstrated the potential of CBG in combination with antibiotic therapy to combat increasing instances of drug resistance in bacteria. CBG with polymyxin B inhibited the growth of Gram-negative pathogens that are resistant to multiple drugs, such as Acinetobacter baumannii, Escherichia coli, Klebsiella pneumonia and Pseudomonas aeruginosa, revealing the broad-spectrum therapeutic potential for cannabinoids. But the compound is not without drawbacks.

“CBG is great at attacking pathogenic bacteria; however, it is toxic to host cells,” Brown said. “Further research and development are needed to ultimately have a safe drug for therapeutic purposes.”

Although the lab has developed creative chemical-biology approaches to characterize novel antimicrobial compounds from natural products, they face additional challenges. “A major hurdle in natural product drug discovery is the chemical synthesis of these molecules,” Brown said.

For this, they collaborated with Jakob Magolan, a McMaster associate professor of biochemistry and biomedical sciences whose research focuses on using organic synthetic chemistry in drug development. “When you take an unusual research project,” Brown said, “it is great to have a team with complementary expertise, as it helps to advance the field (by) rapidly overcoming hurdles.”

Brown hopes to pursue the commercialization of CBG in collaboration with partners in the pharma industry.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Arti Dumbrepatil

Arti Dumbrepatil is a freelance science writer and communicator. With her academic training plus expertise in science communication and writing, she demystifies and transforms complex, jargon-filled science into enjoyable and comprehensible content that resonates with a diverse audience. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

What’s in a diagnosis?
Essay

What’s in a diagnosis?

Sept. 4, 2025

When Jessica Foglio’s son Ben was first diagnosed with cerebral palsy, the label didn’t feel right. Whole exome sequencing revealed a rare disorder called Salla disease. Now Jessica is building community and driving research for answers.

Peer through a window to the future of science
Annual Meeting

Peer through a window to the future of science

Sept. 3, 2025

Aaron Hoskins of the University of Wisconsin–Madison and Sandra Gabelli of Merck, co-chairs of the 2026 ASBMB annual meeting, to be held March 7–10, explain how this gathering will inspire new ideas and drive progress in molecular life sciences.

Glow-based assay sheds light on disease-causing mutations
Journal News

Glow-based assay sheds light on disease-causing mutations

Sept. 2, 2025

University of Michigan researchers create a way to screen protein structure changes caused by mutations that may lead to new rare disease therapeutics.

How signals shape DNA via gene regulation
Journal News

How signals shape DNA via gene regulation

Aug. 19, 2025

A new chromatin isolation technique reveals how signaling pathways reshape DNA-bound proteins, offering insight into potential targets for precision therapies. Read more about this recent MCP paper.

A game changer in cancer kinase target profiling
Journal News

A game changer in cancer kinase target profiling

Aug. 19, 2025

A new phosphonate-tagging method improves kinase inhibitor profiling, revealing off-target effects and paving the way for safer, more precise cancer therapies tailored to individual patients. Read more about this recent MCP paper.

How scientists identified a new neuromuscular disease
Feature

How scientists identified a new neuromuscular disease

Aug. 14, 2025

NIH researchers discover Morimoto–Ryu–Malicdan syndrome, after finding shared symptoms and RFC4 gene variants in nine patients, offering hope for faster diagnosis and future treatments.